Lanean...
A Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease
OBJECTIVE: To determine the safety and pharmacokinetics of etanercept (etanercept, Amgen inc. Thousands Oak, CA) a tumor necrosis factor-α (TNF-α) receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes IVIG and high dose aspirin, but a substantial numbe...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2970727/ https://ncbi.nlm.nih.gov/pubmed/20667551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpeds.2010.06.014 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|